6118 — Austar Lifesciences Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapValue Trap

Annual income statement for Austar Lifesciences, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	R2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,049	1,296	2,015	2,157	1,764
Cost of Revenue
Gross Profit	284	324	479	489	336
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,049	1,265	1,703	2,040	1,794
Operating Profit	0.049	30.7	312	116	-30
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	12.2	41.5	319	120	-34.4
Provision for Income Taxes
Net Income After Taxes	7.46	31.6	273	101	-34.8
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	8.09	33.1	277	87.5	-113
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	8.09	33.1	277	87.5	-113
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.022	0.07	0.213	0.204	-0.069